ClinicalTrials.gg
RecruitingNCT07083804HEPYCAUpdated Nov 20, 2025

Feasibility Study to Diagnose Helicobacter Pylori in the Paediatric Population Using Non-invasive Fecal Analysis

An observational study in HELICOBACTER PYLORI INFECTIONS, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Poitiers University Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
188
Ages
Up to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Communicable Diseases with a site in France — 16 open to participants now, 16 under way, 2 of them phase 3. Communicable Diseases · France.

Planned enrollment
20th of 31
188 · median 334
Started
2025
with 2 others
Observational
31 of 42
12 open now
Primary completion
2027-10
later than 7 of 15 live
Registered
36th of 42
by date

Among the 42 studies in Communicable Diseases with a site in France, this one is the 20th largest by planned enrollment of the 31 observational ones that give a count, is one of 3 that started in 2025, is one of 31 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 36th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

16 of the 42 studies in Communicable Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: Up to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Communicable Diseases with a site in France, or all of them as a file.
02

Study summary

Helicobacter pylori infection is a widespread bacterial disease affecting nearly half of the world's population. In children, the infection displays distinct features versus adults, with lower prevalence, variable symptoms, and differing endoscopic and histological appearances.

Typically acquired in early childhood, its transmission is closely linked to socio-economic disadvantage and overcrowding. Although most infected children are asymptomatic, some develop epigastric pain, dyspepsia, weight loss, or other gastrointestinal disturbances. Chronic infection may eventually lead to mucosal atrophy and intestinal metaplasia, increasing the risk of gastric cancer later in life. Given the limitations and risks of invasive diagnostic methods-especially endoscopy under general anesthesia-there is a critical need for reliable, non-invasive tests. Recent adult studies indicate that stool-based PCR is a promising alternative for both detecting H. pylori and identifying clarithromycin resistance.

The primary objectives of this study are to evaluate the intrinsic diagnostic performance of high-resolution melt PCR (HP PCR) in stools, and to compare these results with those obtained from a conventional work-up, such as gastric biopsies, in a paediatric population. In accordance with prevailing rationality, the principal outcome of this study will be an evaluation of the intrinsic diagnostic capabilities of the proposed method. This will be accomplished by conducting a comparison of the sensitivity and specificity of the PCR test in stools with those of gastric biopsies (reference test).

03

Conditions studied

  • HELICOBACTER PYLORI INFECTIONS

Browse trials for

Keywords

  • Pediatrics
  • Gastroenterology
  • Microbiology
  • Infectious disease
  • Helicobacter pylori
04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children requiring gastric biopsies for H. pylori detection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age \< or = 16 years ;
  • Any indication for gastroscopy in children requiring gastric : gastro-esophageal reflux resistant to proton pump inhibitors (PPIs) or recurrent on discontinuation of PPIs, hematemesis, anemia or unexplained inflammatory syndrome, recurrent vomiting, dysphagia, endoscopic assessment of chronic inflammatory bowel disease with search for H. pylori superinfection ;
  • Patients benefiting from a Social Security scheme or benefiting from one via a third part;
  • Holders of parental authority who have given their to participate in the study and child participants of understanding age who have given their assent.

Non-inclusion Criteria:

  • Antibiotic treatment less than 4 weeks
  • PPIs treatment less than 2 weeks
  • to endoscopic procedure or biopsy.

Exclusion criteria

Exclusion Criteria:

  • Antibiotic therapy prior to stool collection (between inclusion and stool collection, which may be 10 days later)
  • Failure to send/receive stool sample
  • not performed at endoscopy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
188 participants (estimated)
Target follow-up
10 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Pediatric patients

    Pediatric patients consulted/hospitalized for sampling for the presence or absence of Helicobacter pylori.

    Diagnostic Test: Gastric biopsies · Diagnostic Test: Stool sampling

Interventions

  • Diagnostic testGastric biopsies

    After obtaining informed consent, patients receive routine endoscopic procedures with an additional biopsy taken for research purposes. Invasive screening method used in routine care.

  • Diagnostic testStool sampling

    Stool samples are taken and sent within 10 days of the endoscopy. Self-collected stool samples are analyzed using antigen testing and molecular techniques to detect H. pylori and associated resistance mutations. Experimental diagnosis.

06

What researchers measure

Primary outcomes

  1. Evaluate the diagnostic performance of H. pylori PCR in stools

    Diagnostic capabilities will be assessed by the error rate (false positives and negatives) of the stool PCR test, compared with the results of PCR biopsy (reference test).

    Time frame: 10 days

Secondary outcomes

  1. Evaluate the intrinsic diagnostic performance (Se, Sp) of H. pylori PCR in stools

    Intrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity of the stool PCR test with the results of gastric biopsies (reference test).

    Time frame: 10 days

  2. Evaluate the extrinsic diagnostic performance (PPV, NPV) of H. pylori PCR in stools

    Extrinsic diagnostic capabilities will be assessed by comparing the positive and negative predictive values of the stool PCR test with the results of gastric biopsies (reference test).

    Time frame: 10 days

  3. Evaluate the intrinsic diagnostic performance (Se, Sp) of clarithromycin-resistant H. pylori PCR in stools

    Intrinsic diagnostic capabilities will be assessed by comparing the sensitivity, specificity and positive and negative predictive values of the clarithromycin-resistant H. pylori PCR test in stools with those of gastric biopsies (reference test).

    Time frame: 10 days

  4. Evaluate the extrinsic diagnostic performance (PPV, NPV) of clarithromycin-resistant H. pylori PCR in stools

    Extrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity, as well as the positive and negative predictive values, of the clarithromycin-resistant H. pylori PCR test in stools with the results of gastric biopsies (reference test).

    Time frame: 10 days

  5. Evaluate the intrinsic and extrinsic diagnostic performance of H. pylori PCR and H. pylori antigen in stools

    Intrinsic and extrinsic diagnostic capabilities will be assessed by comparing the sensitivity and specificity and positive and negative predictive values of the stool antigen test with the results of gastric biopsies (reference test).

    Time frame: 10 days

  6. Evaluate the intrinsic diagnostic performance (Se, Sp) of H. pylori PCR in stools

    Intrinsic diagnostic capabilities will be assessed by the sensitivity and specificity and positive and negative predictive values of the stool PCR test, and compared with stool antigen results.

    Time frame: 10 days

  7. Evaluate the extrinsic diagnostic performance (PPV, NPV) of H. pylori PCR in stool

    Extrinsic diagnostic capabilities will be assessed by the sensitivity and specificity and positive and negative predictive values of the stool PCR test, and compared with stool antigen results.

    Time frame: 10 days

  8. Evaluate the adherence of a stool self-sampling for H. pylori

    Adherence to stool sampling will be assessed by the number of stool samples received in the population analyzed out of the number of patients included

    Time frame: 10 days

  9. Analyze resistance profiles to the various antibiotics used in Helicobacter pylori eradication therapy

    Analyze resistance profiles to the various antibiotics used in Helicobacter pylori eradication therapy in relation to biological test results (PCR in biopsy and stool, stool antigens) and clinical presentation. Resistance profiles will be expressed in micrograms per mL and interpreted in accordance with the current guidelines of the Antibiogram Committee of the French Microbiology Society.

    Time frame: 10 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 128 non-industry observational studies under Communicable Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 142 studies reached it within 37 months; a quarter within 17 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 24, 2025
StartActual
Oct 7, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Mar 2028
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083804
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Oct 7, 2025
Primary completion
Oct 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 20, 2025

Study contacts

Mailen DAGORRET, MD
Contact
Mailen.DAGORRET@chu-poitiers.fr
+33549443389
Celine ABONNEAU, Project manager
Contact
celine.abonneau@chu-poitiers.fr
+33516604233

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion